For SLC35A2-related patients, reported in FCD type I, treatment with exogenous galactose may be an interesting possibility, as observed previously in two cases (Dörre et al., 2015; Demos et al., 2019). The gene discussed is SLC35A2; the disease is isolated focal cortical dysplasia type I.